)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International (KNSA) investor relations material
Kiniksa Pharmaceuticals International Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 2026 ARCALYST revenue was $286.0M versus $180.9M a year earlier; net income rose to $47.3M from $18.4M.
2026 ARCALYST revenue guidance increased to $1.045B-$1.050B as adoption grew.
PASTORALE, the pivotal Phase 3 KPL-387 trial, was enrolling and dosing; data are expected in H2 2027.
Financial highlights
Q3 revenue was $286.0M versus $180.9M; 9M revenue was $743.8M versus $475.4M.
Q3 operating income was $54.2M versus $24.0M, and net income was $47.3M versus $18.4M.
Q3 R&D expense was $32.8M versus $24.2M; SG&A was $65.4M versus $49.1M.
ARCALYST collaboration operating profit increased to $211.6M from $126.6M; collaboration expense was $105.8M versus $63.3M.
9M operating cash flow was $144.9M versus $84.1M.
Outlook and guidance
2026 ARCALYST net revenue guidance rose to $1.045B-$1.050B from $980M-$995M.
2026 R&D expense guidance was $160M-$170M and SG&A guidance was $270M-$280M; the current operating plan was expected to remain annually cash-flow positive.
KPL-387 Phase 3 data are expected in H2 2027, with potential commercialization targeted for 2028-2029.
KPL-1161's Phase 1 first-in-human trial was expected to begin by year-end 2026, targeting quarterly subcutaneous dosing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kiniksa Pharmaceuticals International
- Record Q2 revenue and pipeline progress highlight strong growth and future potential.KNSA
Wells Fargo 21st Annual Healthcare Conference - Strong ARCALYST growth, expanding pipeline, and targeted outreach drive future opportunities.KNSACanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 revenue up 55% to $243.6M, net income $25.4M, and guidance raised to $980–$995M.KNSAQ2 2026
- Steady ARCALYST growth and advancing abiprubart trials highlight strong momentum and outlook.KNSA7th Annual Evercore ISI HealthCONx Healthcare Conference
- 62% revenue growth in 2025, strong pipeline progress, and significant market opportunity remain.KNSATD Cowen 46th Annual Health Care Conference
- Commercial momentum and pipeline innovation drive growth, with key clinical readouts ahead.KNSAGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Q2 ARCALYST revenue up 90% YoY to $103.4M; 2024 guidance raised to $405–$415M.KNSAQ2 2024
- Q1 2025 ARCALYST revenue jumped 75%, boosting guidance and returning to profitability.KNSAQ1 2025
- ARCALYST revenue jumped 79% in 2024, with strong 2025 guidance and pipeline progress.KNSAQ4 2024
Next Kiniksa Pharmaceuticals International earnings date
Q4 202623 Feb, 2027
Kiniksa Pharmaceuticals International
Next Kiniksa Pharmaceuticals International earnings date
Q4 202623 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines. The company's work targets debilitating diseases with significant unmet medical needs, particularly within cardiovascular and autoimmune disorders. Kiniksa's portfolio includes products and candidates based on strong biological rationale or validated mechanisms, offering potential differentiation in treatment approaches. The company is known for its flagship product, ARCALYST, which is used to treat certain inflammatory cardiovascular conditions. The company is headquarted in London, UK, and its shares are listed on the NASDAQ.